KemPharm Logo
KemPharm Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Corporate Updates
March 30, 2022 16:05 ET | KemPharm
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today, March 30, 2022, 5:00 p.m. ET Corporate and Regulatory Highlights Announced strategic focus on developing...
KemPharm Logo
KemPharm Announces Full Data Set from Higher-Dose Serdexmethylphenidate (SDX) Phase 1 Clinical Trial
March 21, 2022 07:30 ET | KemPharm
Data demonstrate higher doses of SDX were generally well-tolerated and produced targeted pharmacodynamic effects that may be beneficial for the treatment of idiopathic hypersomnia (IH) and other sleep...
Vitality New.png
FDA Grants Vitality Biopharma Orphan Drug Designation for VBX-100 Prodrug
August 10, 2021 09:00 ET | Vitality Biopharma, Inc
CLEVELAND, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Vitality Biopharma, Inc. (OTC: VBIO) (“Vitality” or the “Company”), an innovation-driven drug development company dedicated to unlocking the therapeutic...
KemPharm Logo
KemPharm to Report Second Quarter 2021 Results
August 05, 2021 07:30 ET | KemPharm
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Thursday, August 12, 2021, 4:30 p.m. ET CELEBRATION, Fla., Aug. 05, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:...
Vitality New.png
Vitality Biopharma Board Update
April 27, 2020 16:52 ET | Vitality Biopharma, Inc
CLEVELAND, April 27, 2020 (GLOBE NEWSWIRE) -- Vitality Biopharma, Inc. (Ticker: VBIO) (“Vitality Biopharma,” “Vitality,” or the “Company”), a corporation dedicated to the development of cannabinoid...
Praxis Bioresearch Awarded $1.5 Million Fast-Track SBIR Grant for Development of Novel Prodrug Stimulant with Abuse-Deterrent Properties
August 07, 2018 08:05 ET | Praxis Bioresearch
MENLO PARK, Calif., Aug. 07, 2018 (GLOBE NEWSWIRE) -- Praxis Bioresearch, a biopharmaceutical company focused on the discovery and development of novel therapeutics for chronic neuropsychiatric and...
Praxis Bioresearch Announces Peer-Reviewed Publication of Positive Data for Novel Prodrug Stimulant with Abuse-Deterrent Properties
March 28, 2018 08:05 ET | Praxis Bioresearch
MENLO PARK, Calif., March 28, 2018 (GLOBE NEWSWIRE) -- Praxis Bioresearch, a biopharmaceutical company focused on the discovery and development of novel therapeutics for chronic neuropsychiatric and...
Praxis Bioresearch Presents Positive Preclinical Data for Novel Prodrug Stimulant with Abuse-Deterrent Properties at ACNP Annual Meeting
December 07, 2017 07:35 ET | Praxis Bioresearch
MENLO PARK, Calif., Dec. 07, 2017 (GLOBE NEWSWIRE) -- Praxis Bioresearch, a biopharmaceutical company focused on the discovery and development of novel therapeutics for chronic neuropsychiatric and...